Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 6Phase 1/2 5Phase 3 2

Status

Recruiting 6Active not recruiting 6

Sponsor Class

OTHER 5NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6

Conditions

Multiple Myeloma 4Smoldering Multiple Myeloma 2

Interventions

pembrolizumab 223Carboplatin 222Specimen Handling 194Cisplatin 192Magnetic Resonance Spectroscopy 165Radiotherapy 153Bevacizumab 143Gemcitabine 136Cyclophosphamide 135Drug Therapy 119Capecitabine 118Paclitaxel 116Oxaliplatin 111Nivolumab 105Biopsy 104venetoclax 103tislelizumab 83Rituximab 83durvalumab 82toripalimab 78Fluorouracil 73Etoposide 72Docetaxel 69Dexamethasone 69sintilimab 67Pemetrexed 67atezolizumab 65Radiosurgery 65Azacitidine 63130-nm albumin-bound paclitaxel 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × iberdomide × Clear all
NCT06179888 2026-05-13

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Recruiting
78 enrolled
Plasma cell

Multiple Myeloma

NCT04776395 2026-04-17

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Emory University

Phase 2 Recruiting
68 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT05272826 2026-03-18

BOREALIS

Canadian Myeloma Research Group

Phase 2 Recruiting
75 enrolled
Plasma cell

Multiple Myeloma

NCT05896228 2026-03-11

Iber-KDd

University of Miami

Phase 2 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma

NCT06762769 2025-08-01

MODIFY

University College, London

Phase 2 Recruiting
63 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT06107738 2025-01-09

IBEX

Barbara Ann Karmanos Cancer Institute

Phase 2 Recruiting
60 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡